Navigation Links
Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year
Date:2/24/2011

PITTSBURGH, Feb. 24, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced its financial results for the three and twelve months ended December 31, 2010, and provided its financial guidance for 2011.  

Financial Results

  • Adjusted diluted EPS of $0.45 for the quarter ended December 31, 2010 compared to $0.33 for the same prior year quarter, an increase of 36%;
  • Adjusted diluted EPS of $1.61 for the year ended December 31, 2010 compared to $1.30 for the prior year, an increase of 24%;
  • Total revenues of $1.43 billion for the quarter ended December 31, 2010 compared to $1.35 billion for the same prior year quarter, an increase of 6%;  
  • Total revenues of $5.45 billion for the year ended December 31, 2010 compared to $5.09 billion for the prior year, an increase of 7%;  
  • On a GAAP basis, diluted EPS of $0.01 for both quarters ended December 31, 2010 and 2009;
  • On a GAAP basis, diluted EPS of $0.68 for the year ended December 31, 2010 compared to $0.30 for the prior year;
  • Cash flow from operating activities of $931 million for the year ended December 31, 2010 compared to $605 million for the prior year, an increase of 54%.  

  • Robert J. Coury, Mylan's Chairman and Chief Executive Officer stated:  "I am very pleased with our performance in 2010, as we delivered solid revenue growth of 8% over the prior year and strong earnings per share growth of 24%. Through our focus on integration and rationalization, we have generated consistent quarterly earnings growth, and a compound annual growth rate (CAGR) of 10% in revenues and 42% in EPS since 2008.  I would like to thank each and every one of our dedicated employees around the globe for their contribution to these achievements."  

    Coury continued:  "2011 marks a new inflection point for Mylan. Going forward, we e
    '/>"/>

    SOURCE Mylan Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

    Related biology technology :

    1. Mylan Confirms First-to-File Patent Challenge Relating to Lescol(R)
    2. Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008
    3. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
    4. Shire Receives FOSRENOL Paragraph IV Notice Letters from Barr Laboratories and Mylan
    5. Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008
    6. Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
    7. Mylan Confirms Four First-to-File Challenges
    8. Mylans Matrix Receives First Tentative FDA Approval Under PEPFAR for Generic Truvada(R)
    9. Mylans Matrix Selected by the Clinton HIV/AIDS Initiative and UNITAID as the Primary Supplier of Five Second-Line and Seven Pediatric HIV/AIDS Treatments
    10. Mylan Receives Tentative FDA Approval for Generic Version of Singulair(R)
    11. Mylan Again Calls for an End to Authorized Generics During 180-Day Exclusivity Period
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/11/2014)... , July 11, 2014  Researchers have ... three-dimensional images. The new technology, called Virtual Finger, ... small structures like neurons and synapses using the ... unique technology makes 3D imaging studies orders of ... at an unprecedented level across many areas of ...
    (Date:7/10/2014)... Toronto, Canada (PRWEB) July 10, 2014 ... often present in very low abundance and are ... quite challenging and time-consuming. , Join presenters Dr. ... Laboratories, and Dr. John Anders, Head of Quality ... mass spectrometer-based approach that can speed detection and ...
    (Date:7/10/2014)... Terascala, the industry leader in ... a former vice president of product management for Flexera ... of marketing. Terascala’s software when combined with leading compute ... highest performance and most reliable solutions for processing big ... channel expansion and broaden its product portfolio. His leadership ...
    (Date:7/10/2014)... CA (PRWEB) July 10, 2014 OMICS ... Bioanalytical techniques during 18-20 August, 2014 at Double Tree ... review the recent developments in Analytical & Bioanalytical research ... globe. , Speaking on this occasion, Dr. Srinubabu Gedela, ... Analytica Acta conference is a remarkable one in bringing ...
    Breaking Biology Technology:Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Terascala Expands Executive Team 2Terascala Expands Executive Team 3A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4
    ... Include: - Initiation of development activities to ... Receipt of GRAS (Generally Recognized As Safe) ... commercialization in the U.S. and elsewhere- New ... Continued activities to support regulatory filings for ...
    ... of Hepatitis C Patients Is Skewed Towards Medicare ... in the General Population, According to a New ... Decision Resources, one of the world,s leading ... healthcare issues, finds that hepatitis C virus patient ...
    ... BioMarin Pharmaceutical,Inc. (Nasdaq: BMRN ) announced ... for the Riquent(R) Phase 3 ASPEN trial, the ... of the trial is,futile. BioMarin and partner ... unblind the data and evaluate all of the ...
    Cached Biology Technology:SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 2SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 3SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 4SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 5SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 6SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 7SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 8SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 9SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 10SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 11SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 12SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 13SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 14Hepatitis C Virus Patient Opportunity Exists Within Many of the Major U.S. Local Markets 2Hepatitis C Virus Patient Opportunity Exists Within Many of the Major U.S. Local Markets 3Results of First Interim Efficacy Analysis for Riquent Phase 3 ASPEN Trial: Continuation of the Trial is Futile 2Results of First Interim Efficacy Analysis for Riquent Phase 3 ASPEN Trial: Continuation of the Trial is Futile 3
    (Date:7/10/2014)... June 27, 2014  Pomerantz LLP has filed ... ("Provectus" or the "Company")(NYSE-MKT: PVCT) and certain of ... States District Court, Middle District of ... of a class consisting of all persons or ... between December 17, 2013 and May 22, 2014, ...
    (Date:7/10/2014)...  Unisys Corporation,s (NYSE: UIS ) subsidiary in ... announced that it has been selected by the Dutch Custodial ... Basic Provision Biometrics solution for penitentiaries across The ... with a solution based on its open standards-based LEIDA ... contract is up to seven years, with the new system ...
    (Date:7/10/2014)... 3, 2014 According to the ... (Swipe And Area), Material (Optical Prism, Pizeoelectric, Capacitive, and ... and Banking & Finance), and Geography - Global Trends ... the global Fingerprint Sensors Market is projected to cross ... of 16.8% from 2014 to 2020. Browse ...
    Breaking Biology News(10 mins):SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 3Fingerprint Sensors Market worth $14.35 Billion by 2020 2Fingerprint Sensors Market worth $14.35 Billion by 2020 3
    ... in his thesis that streams and lakes of Northern Sweden ... the atmosphere. Erik defends his findings at Sweden,s Ume University ... this study accounted for only about four percent of the ... releasing about ten times as much carbon as lakes," says ...
    ... and Drug Administration (FDA) mandates adequate enrollment of women in ... sex differences in device safety and effectiveness are not overlooked. ... of a study evaluating the participation of women and analysis ... a peer-reviewed publication from Mary Ann Liebert, Inc., publishers ...
    ... developed efficiency in the biomass supply and use for ... Energy and Environment Partnership Programme of the Ministry for ... working phases reduce transport costs by 15%. The production ... demonstrated to be financially and technologically sound. , Vietnam ...
    Cached Biology News:Arctic inland waters emit large amounts of carbon 2Biomass supply chains developed by VTT speed up use of bioenergy in Vietnam 2